Guangdong Hengrui Pharma Compares Delivery Methods for SHR-1703 in Healthy Participants
A clinical study is underway to compare the bioavailability and safety of SHR-1703 Injection using two different delivery methods.
Asset / Drug
Drug and asset intelligence for SHR-1703 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.